Early benefit assessments Archives — Page 7 of 9 — German Market Access

Lung cancer drug taken off German market because of no additional benefit rating

On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with

Currently, reserve antibiotics are excluded from a benefit assessment by the G-BA. The G-BA decides whether to accept a new antibiotic onto the

In this post, I’m following up on the key points on the real-world evidence (RWE) data collection in Germany with an IQWiG

In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since

Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in

Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude

This week, we are having a brief look at two brief reports on PROs recently published by the IQWiG. We’ll cover: As

Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:

This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early

In July 2021, we had heard that the G-BA had agreed to joint EU HTAs coming to Germany. Now, on 14 December